Associations between IGF-I, IGF-binding proteins and bone turnover markers in prepubertal obese children

2015 ◽  
Vol 28 (5-6) ◽  
Author(s):  
Joanna Gajewska ◽  
Witold Klemarczyk ◽  
Jadwiga Ambroszkiewicz ◽  
Katarzyna Szamotulska ◽  
Magdalena Chełchowska ◽  
...  
Keyword(s):  
Body Composition ◽  
Body Fat ◽  
Fat Mass ◽  
Body Fat Mass ◽  
Obese Patients ◽  
Obese Children ◽  
Igf Binding Proteins ◽  
Igf I ◽  
Igf Binding ◽  
Igfbp 3

Abstract: To assess the relationships between components of the growth hormone axis, body composition, and bone markers in obese children.: We determined the levels of bone alkaline phosphatase (BALP), C-terminal telopeptide of type I collagen (CTX-I), insulin-like growth factor-I (IGF-I), and IGF-binding proteins (IGFBPs) by immunoenzymatic methods, and body composition by dual-energy X-ray absorptiometry in 45 obese and 20 non-obese children.IGF-I and functional IGFBP-3 levels, IGF-I/total IGFBP-3, and functional IGFBP-3/total IGFBP-3 molar ratios were significantly higher in obese patients than in controls. Multivariate regression analysis in obese patients showed significant associations of BALP with IGF-I (p=0.047) and percent of body fat mass (p=0.002).The relationship of IGF-I and functional IGFBP-3 to BALP may support the concept of IGF-I influence on accelerated bone formation process in obesity. Moreover, IGF-I and percentage of body fat mass may be significant predictors of BALP in obese during the prepubertal period.

Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes

1993 ◽  
Vol 128 (4) ◽  
pp. 313-318 ◽  
Author(s):  
Roman Deyssig ◽  
Herwig Frisch ◽  
Werner F Blum ◽  
Thomas Waldhör
Keyword(s):  
Body Composition ◽  
Body Weight ◽  
Body Fat ◽  
Fat Mass ◽  
Binding Protein ◽  
Controlled Study ◽  
Gh Treatment ◽  
Igf I ◽  
Igf Binding ◽  
Igf Binding Protein

The effect of recombinant GH on strength, body composition and endocrine parameters in power athletes was investigated in a controlled study. Twenty-two healthy, non-obese males (age 23.4±0.5 years; ideal body weight 122±3.1%, body fat 10.1±1.0%; mean±sem) were included. Probands were assigned in a double-blind manner to either GH treatment (0.09U (kg BW)−1 day−1 sc) or placebo for a period of six weeks. To exclude concurrent treatment with androgenic-anabolic steroids urine specimens were tested at regular intervals for these substances. Serum was assayed for GH, IGF-I, IGF-binding protein, insulin and thyroxine before the onset of the study and at two-weekly intervals thereafter. Maximal voluntary strength of the biceps and quadriceps muscles was measured on a strength training apparatus. Fat mass and lean body mass were derived from measurements of skinfolds at ten sites with a caliper. For final evaluation only data of those 8 and 10 subjects in the two groups who completed the study were analyzed. GH, IGF-I and IGF-binding protein were in the normal range before therapy and increased significantly in the GH-treated group. Fasting insulin concentrations increased insignificantly and thyroxine levels decreased significantly in the GH-treated probands. There was no effect of GH treatment on maximal strength during concentric contraction of the biceps and quadriceps muscles. Body weight and body fat were not changed significantly during treatment. We conclude that the anabolic, lipolytic effect of GH therapy in adults depends on the degree of fat mass and GH deficiency. In highly trained power athletes with low fat mass there were no effects of GH treatment on strength and body composition.

scholarly journals POS0570 ASSOCIATION OF BODY FAT MASS AND ITS DISTRIBUTION WITH DISEASE ACTIVITY, PAIN AND DISABILITY IN RHEUMATOID ARTHRITIS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 519.2-520
Author(s):  
O. Lamkhanat ◽  
H. Azzouzi ◽  
I. Linda
Keyword(s):  
Rheumatoid Arthritis ◽  
Body Composition ◽  
Disease Activity ◽  
Body Fat ◽  
Fat Mass ◽  
Health Assessment ◽  
Cross Sectional Study ◽  
Body Fat Mass ◽  
Obese Patients ◽  
Cross Sectional

Background:Rheumatoid arthritis (RA) and body composition are closely related. Recent studies have found a significant association between fat mass and disease activity and disability in RA [1].Objectives:We aimed to study the association between body fat mass and its distribution with disease activity, disability, and pain in RA patients.Methods:This is a cross-sectional study of patients with RA diagnosis according to ACR-EULAR 2010 classification recruited from first January 2021. Those with prior cancer, hyperparathyroidism, hyperthyroidism, diabetes, chronic kidney disease, and cirrhosis were excluded. Body fat mass (BFM) and its distribution (gynoid (GFM), android (AFM), visceral (VFM), limbs (LFM), trunk (TFM)) were measured with dual-energy X-ray absorptiometry (Hologic, Horizon QDR®). Clinical data and laboratory tests of the same day of the DXA scan were analyzed. The associations between BFM and its distribution with disease activity score (DAS28CRP), pain visual analogue scale (VAS), and disability measured by health assessment questionnaire (HAQ) were explored. Obesity was defined as a body mass index (BMI) ≥ of 25kg/m2. Our statistical analysis was based on descriptive study, comparisons and linear regressions using SPSS 20.Results:It is about 69 RA patients. Their mean age was 49.86 ± 14.33 years, mean DAS28CRP was 2.56 ± 1.27, and mean disease duration was 14.84 ± 10.99 years. Sixty-two (89.9%) were women. The mean BMI was 26.46 ± 5.26 kg/m2, and 41 patients were obese (59.4%). Compared with non-obese patients, obese patients had a higher C-reactive protein (p = 0.03). DAS28CRP was higher in obese patients (2.77 ± 1.41 vs 2.25 ± 0.97) but did not reach significance (p = 0.07). We did not find any difference between the two groups regarding pain and disability. In univariate regression analysis, the LFM was positively associated with disease activity (p = 0.001; β = 0.38), pain (p = 0.001; β = 0.38) and disability (p = 0.007; β = 0.32). Adjusted on BMI, LDL cholesterol, triglyceride, cumulative dose of corticosteroid, disease and corticosteroid duration, menopause duration, dose and duration of methotrexate, we found a significant association between LFM, disability (p = 0.02; β = 0.51), disease activity (p = 0.02; β = 0.54) and pain (p = 0.009; β = 0.57). However, we had no association between disease activity, pain, and disability with BFM and the other components.Conclusion:Limbs fat mass was significantly associated with the activity, disability, and pain in RA patients.References:[1]Kyeong Min Son, Seong Hun Kang, Young Il Seo, Hyun Ah Kim. Association of body composition with disease activity and disability in rheumatoid arthritis. Korean J Intern Med. 2021 Jan;36(1):214-222.Disclosure of Interests:None declared

scholarly journals Uric acid is associated with adiposity factors, especially with fat mass reduction during weight loss in obese children and adolescents

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Yang Niu ◽  
Xue-lin Zhao ◽  
Hui-juan Ruan ◽  
Xiao-meng Mao ◽  
Qing-ya Tang
Keyword(s):  
Weight Loss ◽  
Body Composition ◽  
Uric Acid ◽  
Children And Adolescents ◽  
Body Fat ◽  
Fat Mass ◽  
Dietary Control ◽  
Obese Children ◽  
Fat Percentage ◽  
Before And After

Abstract Background Current adult studies suggest that uric acid (UA) is associated with body fat, but the relationship in obese children is unclear. Thus, we aim to evaluate the association between uric acid and body composition of obese children. Methods A total of 79 obese children were included in this study, and 52 children (34 boys and 18 girls) underwent a 6-week weight loss camp, including 34 boys and 18 girls. Six-week weight-loss interventions were performed on all participants through aerobic exercise and appropriate dietary control. Laboratory tests and body composition were collected before and after the intervention. Results Before the intervention, correlation analysis demonstrated that uric acid was positively correlated with height, weight, body mass index (BMI), waist circumference, hip circumference, fat mass (FM), and free fat mass (FFM) with adjusting for age and gender (P < 0.05). After 6 weeks of intervention, the participants gained 3.12 ± 0.85 cm in height, body fat percentage decreased by 7.23 ± 1.97%, and lost 10.30 ± 2.83 kg in weight. Univariate and multivariate analysis indicated that uric acid at baseline was associated with FM reduction during weight loss (P < 0.05). Conclusions This study is the first report that uric acid is associated with BMI and FM, and may play an important role in the reduction of FM during weight loss in obese children and adolescents. The interaction between UA and adiposity factors and its underlying mechanisms need to be further explored. Trial registration This study was registered in Clinical Trials.gov (NCT03490448) and approved by the Ethics Committee of Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

scholarly journals IGFs and IGF-binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH

2001 ◽  
pp. 237-243 ◽  
Author(s):  
X Zhou ◽  
KY Loke ◽  
CC Pillai ◽  
HK How ◽  
HK Yap ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Growth Retardation ◽  
Bone Age ◽  
Gh Treatment ◽  
Igf Binding Proteins ◽  
Steroid Dependent ◽  
Igf I ◽  
Igf Binding ◽  
Pre Treatment ◽  
Igfbp 3

OBJECTIVE: Children with steroid-dependent nephrotic syndrome (SDNS), despite being in remission on glucocorticoids, continue to have growth retardation and short stature. The mechanism is uncertain as both chronic glucocorticosteroids and the nephrotic syndrome may independently affect growth. We investigated the changes in the IGFs and IGF-binding proteins (IGFBPs) in a group of short SDNS children, and studied the changes prospectively with 1 year's treatment with GH. DESIGN AND METHODS: Total and 'free' IGF-I, IGFBP-3 and acid-labile subunit (ALS) were studied in eight SDNS boys (mean age=12.6 years; mean bone age=9.1 years) on long term oral prednisolone (mean dose 0.46 mg/kg per day) before, during, and after, 1 year's treatment with GH (mean dose 0.32 mg/kg per week). Pretreatment comparisons were made with two control groups, one matched for bone age (CBA; mean bone age=9.2 years), and another for chronological age (CCA; mean chronological age=13 years). Subsequently, three monthly measurements of serum and urine IGFBPs were carried out in the GH-treated SDNS patients using Western ligand blot and Western immunoblot. RESULTS: Pre-treatment serum total IGF-I levels and the IGF-I/IGFBP-3 ratio were elevated significantly in SDNS compared with CBA, and were similar to CCA. Serum free IGF-I levels were elevated significantly compared with both control groups, but serum IGFBP-3 did not differ significantly. Urinary IGFBP-2, IGFBP-3 and ALS were detectable in the SDNS children only. With GH treatment, IGF-I and IGFBP-3, but not IGF-II, increased significantly compared with pre-treatment values, and returned to baseline after cessation of GH treatment. Urinary IGFBPs did not change significantly with GH treatment. CONCLUSIONS: There is persistent urinary loss of IGFBP-2, IGFBP-3 and ALS in children with SDNS in remission with growth retardation. However, the significant elevation in serum IGF-I suggests that glucocorticoid-induced resistance to IGF is the main factor responsible for the persistent growth retardation in these children. Exogenous GH was able to overcome this resistance by further increasing serum IGF-I.

Circulating insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs) and tissue mRNA levels of IGFBP-2 and IGFBP-4 in the ovine fetus

1995 ◽  
Vol 145 (3) ◽  
pp. 545-557 ◽  
Author(s):  
J M Carr ◽  
J A Owens ◽  
P A Grant ◽  
P E Walton ◽  
P C Owens ◽  
...  
Keyword(s):  
Binding Proteins ◽  
Mrna Level ◽  
Common Factor ◽  
Late Gestation ◽  
Mrna Levels ◽  
Igf Binding Proteins ◽  
Fetal Sheep ◽  
Igf I ◽  
Igf Binding ◽  
Igfbp 3

Abstract The IGF-binding proteins (IGFBPs) are a family of at least six structurally related proteins, which bind the IGFs and modulate their actions, including the regulation of preand postnatal growth. In this study we have examined the relationship between circulating and tissue mRNA levels of IGFBPs and related this to circulating IGFs in the fetal sheep over the gestational period when rapid growth and development occurs. Circulating IGFBP-2, as measured by Western ligand blot (WLB), increases between early and mid gestation, remains high, then declines throughout late gestation (P=0·0002). Circulating IGFBP-3 increases throughout gestation, as measured by WLB or RIA (P=0·04 and P=0·0001 respectively), as does circulating IGFBP-4 (P=0·004). These ontogenic changes in circulating IGFBPs-2 and -4 are paralleled by changes in liver mRNA for these proteins and, for IGFBP-2, by those in kidney IGFBP-2 mRNA also. This suggests that liver and kidney may be the primary contributors to circulating IGFBP-2 and the liver to circulating IGFBP-4. IGFBP-2 mRNA is present in the heart and lung in early gestation but barely detectable in these tissues after approximately 60 days gestation. IGFBP-4 mRNA is also present in the heart in early but not late gestation, but is abundant in the lung throughout gestation. These results demonstrate tissue specific and developmental regulation of IGFBPs-2 and -4 at the mRNA level. To assess any role the circulating IGFs may play in mediating these changes in IGFBPs, or vice versa, both plasma IGF-I and IGF-II were measured by RIA. Circulating IGF-I increases as gestation progresses (P=0·0001), while circulating IGF-II increases between early and mid gestation, remains high (P=0·01), then declines. Circulating IGF-I is positively correlated with fetal weight (r=0·66, P=0·03), circulating IGFBP-3 (r=0·54, P=0·01) and IGFBP-4 (r=0·52, P=0·01). Circulating IGF-II positively correlates with circulating IGFBP-2 (r=0·48, P=0·02) throughout gestation and at 1 day postnatally. These relationships are consistent with circulating IGF-I influencing IGFBPs-3 and -4, and similarly, IGF-II determining IGFBP-2, or vice versa. Alternatively, these correlations may reflect coordinate regulation of IGF and IGFBP by a common factor. Journal of Endocrinology (1995) 145, 545–557

scholarly journals Exogenous GLP-2 and IGF-I induce a differential intestinal response in IGF binding protein-3 and -5 double knockout mice

2012 ◽  
Vol 302 (8) ◽  
pp. G794-G804 ◽  
Author(s):  
Sangita G. Murali ◽  
Adam S. Brinkman ◽  
Patrick Solverson ◽  
Wing Pun ◽  
John E. Pintar ◽  
...  
Keyword(s):  
Relative Mass ◽  
Jejunal Mucosa ◽  
Double Knockout ◽  
Igf Binding Proteins ◽  
Male Adult ◽  
Adult Mice ◽  
Igf I ◽  
Igf Binding ◽  
Mucosal Growth ◽  
Igfbp 3

Glucagon-like peptide-2 (GLP-2) action is dependent on intestinal expression of IGF-I, and IGF-I action is modulated by IGF binding proteins (IGFBP). Our objective was to evaluate whether the intestinal response to GLP-2 or IGF-I is dependent on expression of IGFBP-3 and -5. Male, adult mice in six treatment groups, three wild-type (WT) and three double IGFBP-3/-5 knockout (KO), received twice daily intraperitoneal injections of GLP-2 (0.5 μg/g body wt), IGF-I (4 μg/g body wt), or PBS (vehicle) for 7 days. IGFBP-3/-5 KO mice showed a phenotype of lower plasma IGF-I concentration, but greater body weight and relative mass of visceral organs, compared with WT mice ( P < 0.001). WT mice showed jejunal growth with either IGF-I or GLP-2 treatment. In KO mice, IGF-I did not stimulate jejunal growth, crypt mitosis, sucrase activity, and IGF-I receptor (IGF-IR) expression, suggesting that the intestinotrophic actions of IGF-I are dependent on expression of IGFBP-3 and -5. In KO mice, GLP-2 induced significant increases in jejunal mucosal cellularity, crypt mitosis, villus height, and crypt depth that was associated with increased expression of the ErbB ligand epiregulin and decreased expression of IGF-I and IGF-IR. This suggests that in KO mice, GLP-2 action in jejunal mucosa is independent of the IGF-I system and linked with ErbB ligands. In summary, the intestinotrophic actions of IGF-I, but not GLP-2, in mucosa are dependent on IGFBP-3 and -5. These findings support the role of multiple downstream mediators for the mucosal growth induced by GLP-2.

scholarly journals Aerobic exercise-induced changes in body composition and blood lipids in young women

Medicina ◽  
2010 ◽  
Vol 46 (2) ◽  
pp. 129 ◽  
Author(s):  
Arvydas Stasiulis ◽  
Asta Mockienė ◽  
Daiva Vizbaraitė ◽  
Pranas Mockus
Keyword(s):  
Body Mass Index ◽  
Body Composition ◽  
Body Weight ◽  
Body Mass ◽  
Body Fat ◽  
Fat Mass ◽  
Blood Lipids ◽  
Density Lipoprotein ◽  
Body Fat Mass ◽  
Cycling Training

The objective of the study was to assess changes in body composition, blood lipid and lipoprotein concentrations in 18–24-year-old women during the period of two-month aerobic cycling training. Material and methods. Young, healthy, nonsmoking women (n=19) volunteered to participate in this study. They were divided in two groups: experimental (E, n=10) and control (C, n=9). The subjects of group E exercised 3 times a week with intensity of the first ventilatory threshold and duration of 60 min. The group C did not exercise regularly over a two-month period of the experiment. The subjects of group E were tested before and after 2, 4, 6 and 8 weeks of the experiment. The participants of group C were tested twice with an eight-week interval. Results. Body weight, body mass index, body fat mass, and triacylglycerol (TAG) concentration decreased and high-density lipoprotein cholesterol (HDL-ch) concentration increased after the 8-week training program in the experimental group (P<0.05). Blood total cholesterol (Tch) and low-density lipoprotein cholesterol (LDL-ch) concentrations did not change significantly. Body weight and body mass index started to decrease after 2 weeks of the experiment, but significant changes were observed only after 6 and 8 weeks. Body fat mass was significantly decreased after 2 and 8 weeks of aerobic training. A significant increase in HDL-ch concentration was observed after 4, 6, and 8 weeks. A significant decrease in TAG concentration was observed after 2-week training. No significant changes in all the parameters except TAG (it was slightly increased) were seen in the control group. Conclusions. The two-month aerobic cycling training (within VT1, 60-min duration, three times a week) may induce significant changes in the parameters of body composition – body weight, body mass index, body fat mass, and blood lipids – in young women. The following significant changes were observed: TAG level decreased after 2 weeks, body mass and body mass index decreased after 6 weeks, body fat mass decreased and HDL-ch level increased after 8 weeks. Peak oxygen uptake increased after 4 weeks.

Sign in / Sign up

Export Citation Format

Share Document